ChromoCure's Technology and Theoretical Approach to Cancer Further Affirmed by Recent $720,000 Donation to The Cancer Society fo
2010年2月8日 - 10:30PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) -- The Company announces that,
on the heals of launching its groundbreaking collaborate cancer
therapeutics and cure initiative: "Project Boveri: Find the Cure,"
it is encouraged by the recent donation by Dr. Lawrence Tseu, a
retired Honolulu dentist and noted philanthropist, and whose late
wife was a long time cancer patient, of $720,000 to the American
Cancer Society Hawaii Pacific for research to stop breast cancer
from spreading to other parts of the body utilizing the chromosomal
(aneuploidy) theory of Cancer.
Wael ElShamy, a Cancer Research Center of Hawaii researcher,
discovered that a certain molecule plays a key role in breast
cancer metastasis, ACS said. When the molecule is active in breast
cancer cells, it promotes an abnormal number of chromosomes, called
aneuploidy. Jackie Young, ACS Hawaii Pacific chief staff officer
for mission, said, "This very generous gift will fund an important
research project that could improve how breast cancer is treated
and dramatically increase the survival rate."
ChromoCure has long championed the chromosomal/aneuploidy theory
of cancer. This theory has been proven by recent findings by third
party research and publications including the Mayo Clinic. The
company therefore announced the launch of its Cancer Therapy and
Cure initiative, "Project Boveri: Find the Cure"; a collaborative
expansion of its research into detecting cancer in its earliest
stages, greatly aiding the ability to treat or cure it.
Not only has ChromoCure's theoretical approach to cancer been
validated, its proprietary Chromosomal Scanner technology, as
demonstrated in the Company's recently published collaborative
clinic testing, has been proven a reliable and effective automated
technological system to detect aneuploid cells in real-world
specimens, that detection of aneuploid cells is diagnostic of
cervical lesions, and that the Chromosomal Scanner possesses superb
performance at not only detecting cancer but achieving the near
theoretical maximum agreement with the clinic's error containing
data.
The Company's proprietary technology and pioneering knowledge of
cancer's chromosomal properties invites very effective, non-toxic
therapeutic and disease eradication strategies. ChromoCure's
understanding of cancer's chromosomal peculiarities provides the
most promising avenue for treatment and cure and reinforces its
pioneering status.
About ChromoCure
ChromoCure develops proprietary technologies based on the
chromosomal theory of cancer. The Company has proprietary
technology, designs, protocols, and algorithms for cancer
detection. The Company's technology has been proven to have an
effective accuracy of 100% for all cancers at all stages with zero
false positives or false negatives and an effective 100%
specificity. The Company believes its technology will become the
worldwide gold standard for cancer detection, therapy and cure
research. The Company also applies its technology and understanding
of cancer's unique genomic characteristics in the area of
therapeutics and disease eradication as part of its ongoing
research efforts.
Safe-Harbor Statement This release
contains statements or projections regarding future performance
that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated herein by reference) and should be read
before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 8 2024 まで 9 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 9 2023 まで 9 2024